Seattle Genetics, Inc. (SGEN) Insider Sells $599,700.00 in Stock

Seattle Genetics, Inc. (NASDAQ:SGEN) insider Vaughn B. Himes sold 10,000 shares of Seattle Genetics stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $59.97, for a total transaction of $599,700.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Vaughn B. Himes also recently made the following trade(s):

  • On Friday, September 8th, Vaughn B. Himes sold 10,000 shares of Seattle Genetics stock. The shares were sold at an average price of $53.22, for a total transaction of $532,200.00.

Seattle Genetics, Inc. (NASDAQ:SGEN) opened at $56.75 on Thursday. Seattle Genetics, Inc. has a fifty-two week low of $45.31 and a fifty-two week high of $71.32.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.23. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The firm had revenue of $135.29 million for the quarter, compared to the consensus estimate of $112.76 million. During the same period in the previous year, the company earned ($0.23) earnings per share. The company’s quarterly revenue was up 27.3% on a year-over-year basis. equities research analysts expect that Seattle Genetics, Inc. will post -0.93 earnings per share for the current fiscal year.

A number of research analysts have weighed in on SGEN shares. Cann started coverage on shares of Seattle Genetics in a research note on Wednesday, November 8th. They issued a “hold” rating on the stock. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Seattle Genetics in a report on Monday, October 23rd. Goldman Sachs Group reiterated a “neutral” rating and issued a $64.00 price objective on shares of Seattle Genetics in a report on Friday, October 6th. TheStreet upgraded shares of Seattle Genetics from a “d” rating to a “c” rating in a report on Thursday, November 16th. Finally, Jefferies Group reiterated a “buy” rating and issued a $53.00 price objective on shares of Seattle Genetics in a report on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $63.53.

Several institutional investors have recently made changes to their positions in the company. Aperio Group LLC boosted its position in shares of Seattle Genetics by 0.3% in the second quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock valued at $1,640,000 after acquiring an additional 91 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Seattle Genetics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 4,824 shares of the biotechnology company’s stock valued at $250,000 after acquiring an additional 299 shares during the period. Prudential Financial Inc. boosted its position in shares of Seattle Genetics by 6.8% in the second quarter. Prudential Financial Inc. now owns 6,291 shares of the biotechnology company’s stock valued at $325,000 after acquiring an additional 400 shares during the period. Tredje AP fonden boosted its position in shares of Seattle Genetics by 3.7% in the second quarter. Tredje AP fonden now owns 15,470 shares of the biotechnology company’s stock valued at $800,000 after acquiring an additional 550 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Seattle Genetics by 1.1% in the second quarter. Alliancebernstein L.P. now owns 57,241 shares of the biotechnology company’s stock valued at $2,962,000 after acquiring an additional 603 shares during the period. 98.96% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Seattle Genetics, Inc. (SGEN) Insider Sells $599,700.00 in Stock” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://transcriptdaily.com/2017/12/07/seattle-genetics-inc-sgen-insider-sells-599700-00-in-stock.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply